The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several ...

Drug manufacturer Eli Lilly's weight loss pill has completed late-stage trials for people with type 2 diabetes. The pill could offer an alternative to injectables. US general details China ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

If approved, the pill is expected to be far easier to administer than current injectables - and far easier to manufacture Eli Lilly ... Novo's injectable Ozempic in diabetes, and shows weight loss ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Shares of Eli Lilly (LLY) jumped 16% Thursday morning to lead S&P 500 gainers after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker ...

Eli Lilly on Thursday reported ... raking in $3.84 billion in revenue. That's up a whopping 113% from the same period a year ago. The company's weight loss drug Zepbound also beat estimates ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...